Linked Life Data

6197336

Source:http://linkedlifedata.com/resource/pubmed/id/6197336

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6197336rdf:typepubmed:Citationlld:pubmed
pubmed-article:6197336lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:6197336lifeskim:mentionsumls-concept:C0027788lld:lifeskim
pubmed-article:6197336lifeskim:mentionsumls-concept:C0001563lld:lifeskim
pubmed-article:6197336lifeskim:mentionsumls-concept:C0021547lld:lifeskim
pubmed-article:6197336lifeskim:mentionsumls-concept:C0004462lld:lifeskim
pubmed-article:6197336lifeskim:mentionsumls-concept:C0439830lld:lifeskim
pubmed-article:6197336lifeskim:mentionsumls-concept:C1708528lld:lifeskim
pubmed-article:6197336lifeskim:mentionsumls-concept:C0243067lld:lifeskim
pubmed-article:6197336lifeskim:mentionsumls-concept:C2348243lld:lifeskim
pubmed-article:6197336pubmed:issue5lld:pubmed
pubmed-article:6197336pubmed:dateCreated1984-2-24lld:pubmed
pubmed-article:6197336pubmed:abstractTextThe effects of orally-administered myo-inositol have been compared with those of an aldose reductase inhibitor on acute neurological defects in experimentally diabetic rats. Three groups of streptozotocin-treated diabetic rats (50 mg/kg, IP) together with three groups of age-matched controls (saline, IP) were compared. One pair of groups (control and diabetic) were untreated for 3 weeks, another pair of groups received daily oral myo-inositol (667 mg/kg) and the third pair received an aldose reductase inhibitor (ICI 105 552; 50 mg . kg-1, day-1, orally). The untreated diabetic group showed statistically significant deficits in accumulation, proximal to 24 h sciatic nerve constrictions, of choline acetyltransferase activity by comparison with untreated controls (2.8 +/- 0.4 versus 5.1 +/- 0.4 nmol acetylcholine . h-1 . nerve-1; p less than 0.001). The untreated diabetic rats also showed a fall in motor nerve conduction velocity of 6.2 +/- 0.7 m/s which was statistically significant (p less than 0.001). Treatment of the diabetic group with myo-inositol prevented the development of both defects of axonal transport and conduction velocity; both measurements were similar to those of the myo-inositol treated control rats. Likewise the diabetic rats which received aldose reductase inhibitor showed prevention of both defects. Nerves from untreated diabetic rats showed marked sorbitol accumulation and a statistically significant reduction in myo-inositol content by comparison with the untreated controls (sorbitol, 1.56 +/- 0.22 versus 0.8 +/- 0.01 and myo-inositol, 1.47 +/- 0.10 versus 2.3 +/- 0.10 nmol/mg; p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:6197336pubmed:languageenglld:pubmed
pubmed-article:6197336pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6197336pubmed:citationSubsetIMlld:pubmed
pubmed-article:6197336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6197336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6197336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6197336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6197336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6197336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6197336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6197336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6197336pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6197336pubmed:statusMEDLINElld:pubmed
pubmed-article:6197336pubmed:monthNovlld:pubmed
pubmed-article:6197336pubmed:issn0012-186Xlld:pubmed
pubmed-article:6197336pubmed:authorpubmed-author:TomlinsonD...lld:pubmed
pubmed-article:6197336pubmed:authorpubmed-author:MayerJ HJHlld:pubmed
pubmed-article:6197336pubmed:issnTypePrintlld:pubmed
pubmed-article:6197336pubmed:volume25lld:pubmed
pubmed-article:6197336pubmed:ownerNLMlld:pubmed
pubmed-article:6197336pubmed:authorsCompleteYlld:pubmed
pubmed-article:6197336pubmed:pagination433-8lld:pubmed
pubmed-article:6197336pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:meshHeadingpubmed-meshheading:6197336-...lld:pubmed
pubmed-article:6197336pubmed:year1983lld:pubmed
pubmed-article:6197336pubmed:articleTitlePrevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.lld:pubmed
pubmed-article:6197336pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6197336pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6197336lld:pubmed